Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pliant Therapeutics stock | $26.24

Own Pliant Therapeutics stock in just a few minutes.

Posted

Fact checked

Pliant Therapeutics, Inc is a biotechnology business based in the US. Pliant Therapeutics shares (PLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pliant Therapeutics employs 70 staff and has a trailing 12-month revenue of around USD$94.4 million.

How to buy shares in Pliant Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pliant Therapeutics. Find the stock by name or ticker symbol: PLRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pliant Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$26.24, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pliant Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Pliant Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pliant Therapeutics share price

Use our graph to track the performance of PLRX stocks over time.

Pliant Therapeutics shares at a glance

Information last updated 2021-01-18.
Latest market closeUSD$26.24
52-week rangeUSD$19.425 - USD$35.63
50-day moving average USD$26.6409
200-day moving average USD$25.1202
Wall St. target priceUSD$43.33
PE ratio 42.7543
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.2724

Buy Pliant Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pliant Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pliant Therapeutics price performance over time

Historical closes compared with the close of $26.24 from 2020-12-09

1 week (2021-01-13) N/A
1 month (2020-12-24) 3.27%
3 months (2020-10-23) 10.39%
6 months (2020-07-20) N/A
1 year (2020-01-20) N/A
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

Is Pliant Therapeutics under- or over-valued?

Valuing Pliant Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pliant Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pliant Therapeutics's P/E ratio

Pliant Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, Pliant Therapeutics shares trade at around 43x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pliant Therapeutics's EBITDA

Pliant Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.8 million.

The EBITDA is a measure of a Pliant Therapeutics's overall financial performance and is widely used to measure a its profitability.

Pliant Therapeutics financials

Revenue TTM USD$94.4 million
Operating margin TTM 20.75%
Gross profit TTM USD$57.1 million
Return on assets TTM 12.56%
Return on equity TTM 0%
Profit margin 20.83%
Book value N/A
Market capitalisation USD$927.1 million

TTM: trailing 12 months

Shorting Pliant Therapeutics shares

There are currently 929,000 Pliant Therapeutics shares held short by investors – that's known as Pliant Therapeutics's "short interest". This figure is 10.1% up from 843,599 last month.

There are a few different ways that this level of interest in shorting Pliant Therapeutics shares can be evaluated.

Pliant Therapeutics's "short interest ratio" (SIR)

Pliant Therapeutics's "short interest ratio" (SIR) is the quantity of Pliant Therapeutics shares currently shorted divided by the average quantity of Pliant Therapeutics shares traded daily (recently around 109810.87470449). Pliant Therapeutics's SIR currently stands at 8.46. In other words for every 100,000 Pliant Therapeutics shares traded daily on the market, roughly 8460 shares are currently held short.

However Pliant Therapeutics's short interest can also be evaluated against the total number of Pliant Therapeutics shares, or, against the total number of tradable Pliant Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pliant Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Pliant Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0355% of the tradable shares (for every 100,000 tradable Pliant Therapeutics shares, roughly 36 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pliant Therapeutics.

Find out more about how you can short Pliant Therapeutics stock.

Pliant Therapeutics share dividends

We're not expecting Pliant Therapeutics to pay a dividend over the next 12 months.

Pliant Therapeutics overview

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site